AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10652728 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 MIU (22 micrograms) of n‐hIFN beta once a week for 12 additional months
Number of subjects: 60
Study 8682010 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 74
Study 8682010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 2096405 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal cocaine 48 mg/70 kg
Number of subjects: 8
Study 2096405 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal cocaine 96 mg/70 kg
Number of subjects: 8
Study 2096405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 282906 — intervention group
Group type: EXPERIMENTAL
Intervention: Early splenectomy
Number of subjects: 0
Study 282906 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic administration of arabinosyl cytosine and vincristine plus prednisone
Number of subjects: 0
Study 282906 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic administration of arabinosyl cytosine plus thioguanine plus daunomycin
Number of subjects: 0
Study 30675985 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal ropivacaine
Number of subjects: 86
Study 30675985 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 86
Study 28890309 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide - oxygen (60%-40%)
Number of subjects: 40
Study 28890309 — intervention group
Group type: COMPARATOR
Intervention: Oxygen 100%
Number of subjects: 40
Study 26385957 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine
Number of subjects: 19083
Study 26385957 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19083
Study 23600719 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 1% ointment
Number of subjects: 141
Study 23600719 — intervention group
Group type: COMPARATOR
Intervention: Human breast milk
Number of subjects: 141
Study 21681619 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow-derived stem cell (BMC) therapy
Number of subjects: 54
Study 21681619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 18496303 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.25 mg/kg at induction with morphine
Number of subjects: 84
Study 18496303 — intervention group
Group type: COMPARATOR
Intervention: Morphine only (Control)
Number of subjects: 84
Study 16275797 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral therapy (amantadine hydrochloride or oseltamivir phosphate)
Number of subjects: 3
Study 16275797 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir
Number of subjects: 3
Study 16275797 — intervention group
Group type: COMPARATOR
Intervention: Rapid testing
Number of subjects: 3
Study 12384195 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash payment (HKD $10, $20, $40)
Number of subjects: 4850
Study 12384195 — intervention group
Group type: EXPERIMENTAL
Intervention: Lottery entry (HKD $1,000, $2,000, $4,000)
Number of subjects: 4850
Study 12384195 — intervention group
Group type: COMPARATOR
Intervention: No incentive
Number of subjects: 4850
Study 12384195 — intervention group
Group type: EXPERIMENTAL
Intervention: First mailing
Number of subjects: 4850
Study 12384195 — intervention group
Group type: EXPERIMENTAL
Intervention: Second mailing
Number of subjects: 4850
Study 10432877 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium oxalate crystals (COCs) in benign lesions
Number of subjects: 60
Study 10432877 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium oxalate crystals (COCs) in malignant lesions
Number of subjects: 60
Study 10432877 — intervention group
Group type: EXPERIMENTAL
Intervention: Distribution of COCs in benign lesions
Number of subjects: 60
Study 10432877 — intervention group
Group type: EXPERIMENTAL
Intervention: Distribution of COCs in malignant lesions
Number of subjects: 60
Study 10432877 — intervention group
Group type: EXPERIMENTAL
Intervention: Background location of COCs
Number of subjects: 60
Study 7486094 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 1 mg/kg IV
Number of subjects: 96
Study 7486094 — intervention group
Group type: COMPARATOR
Intervention: Morphine 0.1 mg/kg IV
Number of subjects: 96
Study 2150738 — intervention group
Group type: COMPARATOR
Intervention: Epidural lignocaine 2% + epinephrine 1/200,000 + 0 micrograms Sufentanil
Number of subjects: 50
Study 2150738 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural lignocaine 2% + epinephrine 1/200,000 + 20 micrograms Sufentanil
Number of subjects: 50
Study 2150738 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural lignocaine 2% + epinephrine 1/200,000 + 30 micrograms Sufentanil
Number of subjects: 50
Study 2150738 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural lignocaine 2% + epinephrine 1/200,000 + 40 micrograms Sufentanil
Number of subjects: 50
Study 2150738 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural lignocaine 2% + epinephrine 1/200,000 + 50 micrograms Sufentanil
Number of subjects: 50
Study 6903903 — intervention group
Group type: EXPERIMENTAL
Intervention: modeling plus guided practice
Number of subjects: 130
Study 6903903 — intervention group
Group type: EXPERIMENTAL
Intervention: modeling plus self-monitoring
Number of subjects: 130
Study 6903903 — intervention group
Group type: EXPERIMENTAL
Intervention: modeling plus peer support
Number of subjects: 130
Study 6903903 — intervention group
Group type: COMPARATOR
Intervention: modeling alone
Number of subjects: 130
Study 31085219 — intervention group
Group type: EXPERIMENTAL
Intervention: CytoSorb hemoadsorption therapy
Number of subjects: 52
Study 31085219 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 52
Study 29057795 — intervention group
Group type: EXPERIMENTAL
Intervention: Piceatannol (20 mg/day)
Number of subjects: 39
Study 29057795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 27137718 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg opicapone
Number of subjects: 64
Study 27137718 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg opicapone
Number of subjects: 64
Study 27137718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 27137718 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg moxifloxacin
Number of subjects: 64
Study 24042588 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft silicone-based liner (Mucopren Soft)
Number of subjects: 44
Study 24042588 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard acrylic resin-based liner (Kooliner)
Number of subjects: 44
Study 21910337 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Zigui Decoction (MZD)
Number of subjects: 66
Study 19375884 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin-assisted treatment (HAT)
Number of subjects: 0
Study 19375884 — intervention group
Group type: COMPARATOR
Intervention: Methadone maintenance treatment (MMT)
Number of subjects: 0
Study 16283320 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microg alfacalcidol
Number of subjects: 148
Study 16283320 — intervention group
Group type: COMPARATOR
Intervention: 880 IU vitamin D plus 1 g calcium carbonate
Number of subjects: 148
Study 16326667 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls menu-driven incident-reporting system (MDIRS)
Number of subjects: 6
Study 16326667 — intervention group
Group type: COMPARATOR
Intervention: Existing narrative incident report
Number of subjects: 6
Study 12043851 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide Turbuhaler, 200 microg once every night (q.n.)
Number of subjects: 288
Study 12043851 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide Turbuhaler, 100 microg twice‐daily (b.i.d.)
Number of subjects: 288
Study 12043851 — intervention group
Group type: COMPARATOR
Intervention: Placebo b.i.d.
Number of subjects: 288
Study 12043851 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (both regimens)
Number of subjects: 288
Study 10443522 — intervention group
Group type: EXPERIMENTAL
Intervention: PLA rib pins
Number of subjects: 24
Study 10443522 — intervention group
Group type: COMPARATOR
Intervention: Alumina rib pins
Number of subjects: 24
Study 7789372 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy for acute myocardial infarction in patients aged ≤ 40 years
Number of subjects: 269
Study 7789372 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic therapy for acute myocardial infarction in patients aged > 40 years
Number of subjects: 269
Study 2189246 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (M)
Number of subjects: 240
Study 2189246 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of mefloquine + sulfadoxine + pyrimethamine (MSP)
Number of subjects: 240
Study 2189246 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (C)
Number of subjects: 240
Study 2189246 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest dose of MSP (10 mg/kg M + 20 mg/kg S + 1.0 mg/kg P)
Number of subjects: 240
Study 494166 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent sequential calf compression
Number of subjects: 199
Study 494166 — intervention group
Group type: COMPARATOR
Intervention: Control (no calf compression)
Number of subjects: 199
Study 30427582 — intervention group
Group type: EXPERIMENTAL
Intervention: Emicizumab prophylaxis (Arm A)
Number of subjects: 102
Study 29075107 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized hyaluronan (HA), 150 kDa, administered for 2 weeks
Number of subjects: 11
Study 29075107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 26498221 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 227
Study 26498221 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control Group)
Number of subjects: 227
Study 23463769 — intervention group
Group type: EXPERIMENTAL
Intervention: Bear bile capsule and Huangqi granule daily (Group B)
Number of subjects: 151
Study 23463769 — intervention group
Group type: COMPARATOR
Intervention: Massaging the children's parotid region and melting vitamin C in their mouth daily (Group A)
Number of subjects: 151
Study 23463769 — intervention group
Group type: EXPERIMENTAL
Intervention: Massages and vitamin C as prescribed in Group A, and traditional Chinese medicine as prescribed in Group B (Group C)
Number of subjects: 151
Study 22789511 — intervention group
Group type: EXPERIMENTAL
Intervention: HBVaxPro (Hexavac)
Number of subjects: 410
Study 22789511 — intervention group
Group type: EXPERIMENTAL
Intervention: Engerix‐B (Hexavac)
Number of subjects: 410
Study 22789511 — intervention group
Group type: EXPERIMENTAL
Intervention: HBVaxPro (Infanrix‐Hexa)
Number of subjects: 410
Study 22789511 — intervention group
Group type: EXPERIMENTAL
Intervention: Engerix‐B (Infanrix‐Hexa)
Number of subjects: 410
Study 18556222 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysholm Knee Scale (modified version after removal of the swelling item)
Number of subjects: 157
Study 17531731 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.125%
Number of subjects: 162
Study 17531731 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.125%
Number of subjects: 162
Study 17531731 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% and 0.1%
Number of subjects: 162
Study 15087692 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg pantoprazole daily
Number of subjects: 227
Study 15087692 — intervention group
Group type: COMPARATOR
Intervention: 40 mg esomeprazole daily
Number of subjects: 227
Study 11304654 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide (Al(OH)3) with citrate/citric acid solution (CCA) concurrently with meals
Number of subjects: 10
Study 11304654 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide (Al(OH)3) with citrate/citric acid solution (CCA) 2 hours after meals
Number of subjects: 10
Study 11304654 — intervention group
Group type: COMPARATOR
Intervention: Aluminum hydroxide (Al(OH)3) alone
Number of subjects: 10
Study 11304654 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) with aluminum hydroxide (Al(OH)3)
Number of subjects: 10
Study 11304654 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium acetate with aluminum hydroxide (Al(OH)3)
Number of subjects: 10
Study 9484361 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) treatment (0.4 g/kg/day for 5 days, then 0.4 g/kg every 2 months for 2 years)
Number of subjects: 40
Study 9484361 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) treatment
Number of subjects: 40
Study 9484361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9484361 — intervention group
Group type: COMPARATOR
Intervention: Intravenous immunoglobulin (IVIg) treatment and Placebo
Number of subjects: 40
Study 8306818 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1 g) administered 30 min preoperatively
Number of subjects: 100
Study 8306818 — intervention group
Group type: COMPARATOR
Intervention: Mezlocillin (2 g) and oxacillin (1 g) administered over 24 h (3 injections)
Number of subjects: 100
Study 2785872 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde cardioplegia delivered through the right atrium
Number of subjects: 20
Study 2785872 — intervention group
Group type: COMPARATOR
Intervention: Antegrade cardioplegia
Number of subjects: 20
Study 2785872 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde cardioplegia
Number of subjects: 20
Study 30993478 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Trauma and Self-Care (CBT-TSC)
Number of subjects: 43
Study 30993478 — intervention group
Group type: COMPARATOR
Intervention: HIV voluntary counseling and testing (VCT)-only
Number of subjects: 43
Study 28621019 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit-to-stand test (STST)
Number of subjects: 42
Study 28621019 — intervention group
Group type: COMPARATOR
Intervention: 6-minute walking test (6MWT)
Number of subjects: 42
Study 27234569 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance Commitment Therapy-based group intervention delivered via videoconferencing in six 90 min group sessions
Number of subjects: 0
Study 27234569 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study 24126897 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascending intensity squat protocol (20% 1RM, 40% 1RM, 60% 1RM, 80% 1RM, and maximal isometric half-squat)
Number of subjects: 14
Study 24126897 — intervention group
Group type: COMPARATOR
Intervention: Control condition (resting on a chair after cycling and stretching)
Number of subjects: 14
Study 22650118 — intervention group
Group type: EXPERIMENTAL
Intervention: Soothing‐liver and regulating‐mind group
Number of subjects: 163
Study 22650118 — intervention group
Group type: COMPARATOR
Intervention: Non‐acupoint‐shallow‐puncturing group
Number of subjects: 163
Study 22650118 — intervention group
Group type: COMPARATOR
Intervention: Acupoint‐shallow‐puncturing group
Number of subjects: 163
Study 20939985 — intervention group
Group type: EXPERIMENTAL
Intervention: Pihui Fanggan Sachet (PHFGS) for 45 days
Number of subjects: 239
Study 20939985 — intervention group
Group type: EXPERIMENTAL
Intervention: Pihui Fanggan Sachet (PHFGS) in immunocompromised mice for one week
Number of subjects: 239
Study 20939985 — intervention group
Group type: COMPARATOR
Intervention: Normal control group (no treatment)
Number of subjects: 239
Study 20939985 — intervention group
Group type: COMPARATOR
Intervention: Normal mice (no treatment)
Number of subjects: 239
Study 18036453 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 12056
Study 18036453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12056
Study 15830249 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 12432437 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa administered intravenously (IV)
Number of subjects: 12
Study 12432437 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa administered subcutaneously (SC)
Number of subjects: 12
Study 10354876 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 104
Study 10354876 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrography
Number of subjects: 104
Study 7486743 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic grip strength measurement with forearm rotation
Number of subjects: 15
Study 7486743 — intervention group
Group type: COMPARATOR
Intervention: Static grip strength measurement
Number of subjects: 15
Study 2176097 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine, 3 mg/kg, diluted with physiological saline solution (pH = 6.63 +/‐ 0.05)
Number of subjects: 31
Study 2176097 — intervention group
Group type: COMPARATOR
Intervention: 1% lidocaine, 3 mg/kg, diluted with 1.4% sodium bicarbonate (pH = 7.34 +/‐ 0.05)
Number of subjects: 31
Study 7010531 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenoxolone (Duogastrone)
Number of subjects: 60
Study 7010531 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 60
Study 30230047 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin added to VCD (cyclophosphamide-bortezomib-dexamethasone)
Number of subjects: 58
Study 30230047 — intervention group
Group type: COMPARATOR
Intervention: VCD (cyclophosphamide-bortezomib-dexamethasone) without clarithromycin
Number of subjects: 58
Study 29235594 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-enriched pudding (FEP)
Number of subjects: 19
Study 29235594 — intervention group
Group type: COMPARATOR
Intervention: Low-fat control pudding (CP)
Number of subjects: 19
Study 27274092 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula (HFNC)
Number of subjects: 40
Study 27274092 — intervention group
Group type: COMPARATOR
Intervention: Bag-Valve-Mask (BVM)
Number of subjects: 40
Study 27274092 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula (HFNC) and Bag-Valve-Mask (BVM)
Number of subjects: 40
Study 25282285 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT screening
Number of subjects: 7155
Study 25282285 — intervention group
Group type: COMPARATOR
Intervention: Simulated ACCP management protocol
Number of subjects: 7155
Study 25282285 — intervention group
Group type: EXPERIMENTAL
Intervention: Diameter‐based protocol with volumetry-based nodule diameter
Number of subjects: 7155
Study 25282285 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-based protocol (with thresholds based on lung cancer probability)
Number of subjects: 7155
Study 23045588 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 4760
Study 23045588 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 4760
Study 23045588 — intervention group
Group type: COMPARATOR
Intervention: Normal BMI (< 25 kg/m²)
Number of subjects: 4760
Study 23045588 — intervention group
Group type: COMPARATOR
Intervention: Overweight (BMI 25 to < 30 kg/m²)
Number of subjects: 4760
Study 20182846 — intervention group
Group type: EXPERIMENTAL
Intervention: Manganese chloride tetrahydrate (Bothdel Oral Solution 10) (MCT)
Number of subjects: 57
Study 20182846 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric ammonium citrate (FerriSeltz powder 20%) (FAC)
Number of subjects: 57
Study 20182846 — intervention group
Group type: COMPARATOR
Intervention: No agent
Number of subjects: 57
Study 17287847 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Number of subjects: 362
Study 16122538 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-focus schema therapy (DFST)
Number of subjects: 52
Study 16122538 — intervention group
Group type: COMPARATOR
Intervention: Standard group substance abuse counseling (SAC)
Number of subjects: 52
Study 12031372 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin hydrochloride alone
Number of subjects: 184
Study 12031372 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin alone
Number of subjects: 184
Study 12031372 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin hydrochloride and ciprofloxacin combined
Number of subjects: 184
Study 12031372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 12031372 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 184
Study 11037095 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 35
Study 11037095 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes moving
Number of subjects: 35
Study 8810174 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium (succinylcholine chloride)
Number of subjects: 0
Study 8810174 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 0
Study 1317767 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (500 mg)
Number of subjects: 8
Study 3006228 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 42
Study 3006228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 31461577 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) at 10‐20% maximal voluntary contraction level
Number of subjects: 73
Study 31461577 — intervention group
Group type: COMPARATOR
Intervention: Control group with visible or palpable level of muscle contraction
Number of subjects: 73
Study 31461577 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 73
Study 31461577 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study 29357313 — intervention group
Group type: EXPERIMENTAL
Intervention: UC plus APP‐Me (automated short messaging system)
Number of subjects: 240
Study 29357313 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (UC)
Number of subjects: 240
Study 26398704 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocolized care
Number of subjects: 1243
Study 26398704 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1243
Study 24425420 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized CFAE ablation + PVI
Number of subjects: 86
Study 24425420 — intervention group
Group type: COMPARATOR
Intervention: Selective CFAE ablation targeting continuous electric activity + PVI
Number of subjects: 86
Study 22081113 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidrum
Number of subjects: 80